Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 890 clinical trials
Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy

IMMUNO-BIL is a non-comparative randomized 1:1 phase II study. This study will assess the efficacy and safety of the combination of durvalumab plus tremelimumab with or without weekly paclitaxel in patients with advanced BTC after failure of platinum-based chemotherapy. On the 25th June 2019, the maximum DLT event number was …

  • 05 Feb, 2021
  • 42 locations
TLD-1 a Novel Liposomal Doxorubicin in Patients With Advanced Solid Tumors

TLD-1 is a novel liposomal formulation of doxorubicin (PEG surface) that compared favorably to conventional liposomal formulations of doxorubicin including Caelyx in preclinical in vivo models. Particle features including size, charge distribution, lipid composition and drug release add up to a considerably altered particle behavior compared to Caelyx, potentially explaining …

  • 28 Jan, 2021
  • 6 locations
LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy

Cytotoxic chemotherapy is usually scaled to the body surface area (BSA), and is currently not adjusted to the body proportions of lean and fat (i.e. body composition) of individual patients. Patients with low muscle mass behave like patients "overdosed" with chemotherapy resulted in dose-limiting toxicities (e.g. dose reductions, treatment delays …

  • 24 Jan, 2021
  • 1 location
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR-BioMarkers (BM) Profiling)

PIONeeR study is a prospective, multicenter study without administration of an investigational product. The promotion and funding will be done by the Assistance Publique Hpitaux de Marseille (APHM), the coordination by AMU. There will be 3 principal investigational clinical centres in France: Centre d'Essais Prcoces en Cancrologie de Marseille (CEPCM)-Unit …

  • 08 Apr, 2021
  • 1 location
MethylphenIdate for Fatigue in Haematological Cancer

Cancer related fatigue (CRF) is the most debilitating problem for patients with haematological cancer. CRF severely reduces quality of life (QoL), functional capacity, impacts health behavior, recovery and furthermore no approved treatment exists. In solid cancer methylphenidat (MTP) has been suggested to improve CRF, however patients with haematological cancer has …

  • 22 Jan, 2021
  • 1 location
Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

This is a Phase 1 dose-escalation study to evaluate the safety and tolerability of combination treatment of AZD5363 + Olaparib + Durvalumab and to determine the RP2D in patients with advanced or metastatic solid tumor malignancies. The purpose of this trial is to determine if combination treatment of drugs, Olaparib, …

  • 22 Jan, 2021
  • 1 location
First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI

In Europe, pancreatic cancer (PC) is the 7th most common cancer and the 5th leading cause of cancer death in Europe. Each year, the number of deaths due to prostate cancer is almost as high as the number of new cases diagnosed reflecting the poor prognosis associated with this disease. …

pancreatic adenocarcinoma
  • 22 Jan, 2021
  • 48 locations
CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer

The purpose of this study is to determine the side effects and how effective CyberKnife stereotactic ablative body radiation (SABR) is in patients with prostate cancer. The CyberKnife system is a new type of radiation machine that uses a special system to precisely focus large doses of x-rays on the …

adenocarcinoma of prostate
  • 08 Nov, 2020
  • 1 location
Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma

Some cancers of the oesophagus and stomach express excessive copies of either the cMYC (Myelocytomatosis oncogene) gene, the HER2 (Human epidermal growth factor receptor 2) gene or both. These genes may potentially contribute to the growth and spread of cancer.Ibrutinib is a drug that is already used in the treatment …

  • 23 Jan, 2021
  • 1 location
Synchrotron Radiation to the Treatment of Intracranial Tumors

The purpose of this study is to prove the safety and acceptability of treatment with the Synchrotron radiation by medium-term medical follow-up of the patients.

  • 08 Nov, 2020
  • 1 location